Showing results (31-40 of 94) with videos related to
Sort By:
Pageof 10
Boletin Medico Del Hospital Infantil De Mexico|July 25, 2023
Bowel obstruction related to hydrogel beadsPaulina M Zurita-Martínez, Diana A Guerrero-Reséndiz, Horacio Silva-Ramírez, et al.Journal of Crohn'S & Colitis|May 20, 2024
Magnetic Resonance Imaging Features Indicative of Permanent Colon Damage in Ulcerative Colitis: An Exploratory StudyJordi Rimola, Jesús Castro-Poceiro, Víctor Sapena, et al.Revista Espanola De Enfermedades Digestivas|June 12, 2025
Interobserver variability of endoscopic scores and their subsections in Crohn's disease: a single-center prospective studyLaura Lorenzo González, Daniel Barranco Castro, Victoria Alejandra Jiménez García, et al.Revista Espanola De Enfermedades Digestivas|January 21, 2015
Risk factors for Clostridium difficile diarrhea in patients with inflammatory bowel diseaseAntonio Ramos-Martínez, Jorge Ortiz-Balbuena, Isabel Curto-García, et al.Journal of Crohn'S & Colitis|November 2, 2015
Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort StudyYago González-Lama, Cristina Suárez, Irene González-Partida, et al.Journal of Crohn'S & Colitis|September 10, 2015
Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA RegistryJordi Gordillo, Eduard Cabré, Esther Garcia-Planella, et al.Inflammatory Bowel Diseases|March 18, 2009
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapseJavier P Gisbert, Fernando Bermejo, Jose-Lázaro Pérez-Calle, et al.Microorganisms|May 25, 2024
Prevalence and Risk Factors for Colonization by Multidrug-Resistant Microorganisms among Long-Term Travelers and Recently Arrived MigrantsVíctor Monsálvez, Paula Bierge, María Luisa Machado, et al.Alimentary Pharmacology & Therapeutics|May 5, 2022
Association of golimumab trough concentrations during maintenance with clinical, biological, endoscopic and histologic remission in patients with ulcerative colitisCarlos Taxonera, María Jesús Fernández-Aceñero, David Olivares, et al.Gastroenterologia Y Hepatologia|July 13, 2025
EVOLVE-IBERIA: Real-world evidence on vedolizumab and anti-tumor necrosis factor-α as first- or second-line biologic treatment among patients with ulcerative colitisFrancesc Casellas, Ana Gutiérrez-Casbas, Cristina Rodríguez, et al.Pageof 10